| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anticalin® Proteins as Therapeutic Agents in Human Diseases
|
Rothe, Christine
|
|
2018
|
32 |
3 |
p. 233-243
|
artikel
|
| 2 |
Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis
|
Zozaya, Néboa
|
|
2018
|
32 |
3 |
p. 281-291
|
artikel
|
| 3 |
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review
|
Moots, Robert J.
|
|
2018
|
32 |
3 |
p. 193-199
|
artikel
|
| 4 |
Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy
|
Wege, Anja Kathrin
|
|
2018
|
32 |
3 |
p. 245-266
|
artikel
|
| 5 |
Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy
|
Wege, Anja Kathrin
|
|
|
32 |
3 |
p. 245-266
|
artikel
|
| 6 |
Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland
|
O’Callaghan, J.
|
|
2018
|
32 |
3 |
p. 267-280
|
artikel
|
| 7 |
Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists
|
Emerson, Dana A.
|
|
2018
|
32 |
3 |
p. 221-231
|
artikel
|
| 8 |
SB3 (Ontruzant®): A Trastuzumab Biosimilar
|
Lamb, Yvette N.
|
|
2018
|
32 |
3 |
p. 293-296
|
artikel
|
| 9 |
Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond
|
Karo-Atar, Danielle
|
|
2018
|
32 |
3 |
p. 201-220
|
artikel
|
| 10 |
Tissue Engineering in Osteoarthritis: Current Status and Prospect of Mesenchymal Stem Cell Therapy
|
Im, Gun-Il
|
|
2018
|
32 |
3 |
p. 183-192
|
artikel
|
Tijdschrift beschrijving